FindTrial
Sign In

The role and clinical significance of promoter methylation of tumor suppressor gene in the occurrence and development of gastric cancer

The role and clinical significance of promoter methylation of tumor suppressor gene in the occurrence and development of gastric cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-RCC-08000364
Enrollment
Unknown
Registered
2008-12-30
Start date
2007-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary gastric cancer

Interventions

The experimental group:Chemotherapy was used for gastric cancer patients after their surgical resection
The control group:Chemotherapy was not used for gastric cancer patients after their surgical resection

Sponsors

Anhui Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: Primary malignant tumors of the stomach

Exclusion criteria

Exclusion criteria: Non-primary malignant tumors of the stomach in a variety of metastatic tumors

Design outcomes

Primary

MeasureTime frame
Aberrant promoter CpG islands methylation of p16 gene, RUNX3 gene, CHFR gene, E-cadherin gene and DAPK;—

Countries

China

Contacts

Public ContactHu shilian
hushilian@263.com+86 0551 2283036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026